

| Filing Entity              | COSA   | Study Area Name            | TY 2019-2020<br>Total Eligible<br>Recovery After<br>True-Up<br>Including<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2019-2020<br>Interstate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2019-2020<br>Intrastate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2019-2020<br>Net Recip.<br>Comp. Eligible<br>Recovery<br>(After True-<br>Up) | TY 2019-2020<br>Total of<br>Exogenous Cost<br>Increments | ARC True-Up<br>for TY 2017-<br>2018 | Imputed ARC<br>Revenue From<br>CBOL Lines True<br>Up For TY 2017-<br>2018 | Total of<br>Exogenous Cost<br>True-Ups for TY<br>2017-2018 | TY 2017-2018<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2019-2020<br>Double<br>Recovery<br>Adjustment | TY 2019-2020<br>Expected<br>Maximum<br>ARC Revenue | TY 2019-2020<br>Expected ARC<br>Revenues Assessed<br>Per 51.917(e) And<br>Imputed Per<br>51.917(f)(2) |
|----------------------------|--------|----------------------------|--|---|---|---|--|-------------------------------------|---|--|--|--|--|---|
| Lonsdale Telephone Company | 361422 | Lonsdale Telephone Company | 72,024   | 44,285  | 17,242  | 10,497  | 0  | 0                                   | 0   | 0  | 0  | 0  | 7,920  | 7,920   |

| TY 2019-2020<br>Expected Imputed<br>ARC Revenue From<br>Projected CBOL<br>Lines Per<br>51.917(f)(4), After<br>51.917(f)(5) Limit | TY 2019-2020<br>Expected CAF<br>ICC Support<br>After ARC<br>Imputation<br>For CBOL Lines | TY 2019-2020<br>Projected Res<br>Eligible ARC Lines | TY 2019-2020<br>Projected SLB<br>Eligible ARC<br>Lines | TY 2019-2020<br>Projected MLB<br>Eligible ARC<br>Lines | TY 2019-2020<br>Total Projected<br>CBOL Line<br>Demand | TY 2019-2020<br>Total<br>Projected<br>Revenue From<br>CBOL Lines | TY 2020-2021<br>Total Eligible<br>Recovery After<br>True-Up<br>Including<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2020-2021<br>Interstate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2020-2021<br>Intrastate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2020-2021<br>Net Recip.<br>Comp. Eligible<br>Recovery<br>(After True-<br>Up) | TY 2020-2021<br>Total of<br>Exogenous<br>Cost<br>Increments | ARC True-Up<br>for TY 2018-<br>2019 | Imputed ARC<br>Revenue<br>From CBOL<br>Lines True Up<br>For TY 2018-<br>2019 | Total of<br>Exogenous Cost<br>True-Ups for TY<br>2018-2019 | TY 2018-2019<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2020-2021<br>Double<br>Recovery<br>Adjustment | TY 2020-2021<br>Expected<br>Maximum ARC<br>Revenue |
|--|--|---|--|--|--|--|--|---|---|---|---|-------------------------------------|--|--|--|--|--|
| 0  | 65,074   | 19,320  | 864  | 1,776  | 1,980  | 0  | 75,619   | 47539   | 17119   | 9972  | 0   | 989                                 | 0  | 0  | 0  | 0  | 7560   |

| TY 2020-2021<br>Expected ARC<br>Revenues<br>Assessed Per<br>51.917(e) And<br>Imputed Per<br>51.917(f)(2) | TY 2020-2021<br>Expected Imputed<br>ARC Revenue From<br>Projected CBOL<br>Lines Per<br>51.917(f)(4), After<br>51.917(f)(5) Limit | TY 2020-2021<br>Expected CAF<br>ICC Support<br>After ARC<br>Imputation For<br>CBOL Lines | TY 2020-2021<br>Projected Res<br>Eligible ARC<br>Lines | TY 2020-2021<br>Projected SLB<br>Eligible ARC<br>Lines | TY 2020-2021<br>Projected MLB<br>Eligible ARC<br>Lines | TY 2020-2021<br>Total Projected<br>CBOL Line<br>Demand | TY 2020-2021<br>Total<br>Projected<br>Revenue<br>From CBOL<br>Lines | TY 2021-2022<br>Total Eligible<br>Recovery After<br>True-Up<br>Including<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2021-2022<br>Interstate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2021-2022<br>Intrastate<br>Eligible<br>Recovery<br>(After True-<br>Up) | TY 2021-2022<br>Net Recip.<br>Comp. Eligible<br>Recovery (After<br>True-Up) | TY 2021-2022<br>Total of<br>Exogenous<br>Cost<br>Increments | ARC True-<br>Up for TY<br>2019-2020 | Imputed<br>ARC<br>Revenue<br>From CBOL<br>Lines True<br>Up For TY<br>2019-2020 | Total of<br>Exogenous<br>Cost True-<br>Ups for TY<br>2019-2020 | TY 2019-2020<br>Otherwise<br>Unrecoverable<br>True-Up<br>Revenue | TY 2021-2022<br>Double<br>Recovery<br>Adjustment |
|--|--|--|--|--|--|--|---|--|---|---|---|---|-------------------------------------|--|--|--|--|
| 7560   | 0  | 69930  | 17700  | 900  | 1620   | 6000   | 0   | 71,362   | 45323   | 16188   | 9473  | 0   | 378                                 | 0  | 0  | 0  | 0  |

| TY 2021-2022<br>Expected<br>Maximum<br>ARC Revenue | TY 2021-2022<br>Expected ARC<br>Revenues<br>Assessed Per<br>51.917(e) And<br>Imputed Per<br>51.917(f)(2) | TY 2021-2022<br>Expected Imputed<br>ARC Revenue From<br>Projected CBOL Lines<br>Per 51.917(f)(4), After<br>51.917(f)(5) Limit | TY 2021-2022<br>Expected CAF<br>ICC Support<br>After ARC<br>Imputation For<br>CBOL Lines | TY 2021-2022<br>Projected Res<br>Eligible ARC<br>Lines | TY 2021-2022<br>Projected SLB<br>Eligible ARC<br>Lines | TY 2021-2022<br>Projected MLB<br>Eligible ARC<br>Lines | TY 2021-2022<br>Total Projected<br>CBOL Line<br>Demand | TY 2021-2022<br>Total Projected<br>Revenue From<br>CBOL Lines |
|--|--|---|--|--|--|--|--|---|
| 5796   | 5796   | 900   | 69615  | 15960  | 492  | 1440   | 8700   | 900   |